Vanguard Group
KITE

Vanguard Group’s Kite Pharma, Inc. KITE Stock Holding History

Vanguard Group’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,094,002
Closed -$736M – 4143
2017
Q3 		$736M Buy
4,094,002
+95,733
+2% +$13.3M 0.03% 574
2017
Q2 		$415M Buy
3,998,269
+336,722
+9% +$27.5M 0.02% 784
2017
Q1 		$287M Buy
3,661,547
+507,289
+16% +$31.4M 0.01% 989
2016
Q4 		$141M Buy
3,154,258
+120,122
+4% +$5.89M 0.01% 1398
2016
Q3 		$169M Buy
3,034,136
+98,730
+3% +$5.5M 0.01% 1220
2016
Q2 		$147M Buy
2,935,406
+173,879
+6% +$8.54M 0.01% 1242
2016
Q1 		$127M Buy
2,761,527
+132,185
+5% +$6.4M 0.01% 1315
2015
Q4 		$162M Buy
2,629,342
+506,104
+24% +$35.6M 0.01% 1138
2015
Q3 		$118M Buy
2,123,238
+492,684
+30% +$31M 0.01% 1319
2015
Q2 		$99.4M Buy
1,630,554
+110,285
+7% +$6.29M 0.01% 1531
2015
Q1 		$87.7M Buy
1,520,269
+793,906
+109% +$53.2M 0.01% 1590
2014
Q4 		$41.9M Buy
726,363
+223,543
+44% +$9.41M ﹤0.01% 1924
2014
Q3 		$14.3M Buy
+502,820
New +$12.4M ﹤0.01% 2341

Vanguard Group's KITE Position: Q4 2017 in Review

Vanguard Group sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 4,094,002 shares — an estimated $736M sold.

Vanguard Group first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $736M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • Vanguard Group reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • Vanguard Group sold 4,094,002 Kite Pharma, Inc. shares in Q4 2017, an estimated $736M.
  • Vanguard Group first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
  • Vanguard Group's Kite Pharma, Inc. position peaked at $736M in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on Vanguard Group's 13F filing for Q4 2017, filed 14 Feb 2018.